Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data

Journal of Clinical Oncology

Volumn 23, Issue 1, 2005, Pages 175-183

  Hoang, Tien ^a   Xu, Ronghui ^a   Schiller, Joan H ^a   Bonomi, Philip ^a   Johnson, David H ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NOMOGRAM; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; SKIN METASTASIS; TREATMENT OUTCOME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; LIVER TUMOR; LUNG TUMOR; METASTASIS; MORTALITY; MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SKIN TUMOR; THEORETICAL MODEL;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MODELS, THEORETICAL; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NOMOGRAMS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS;

EID: 15044352688     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.177     Document Type: Article

References (22)

1. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
2. Kelly K, Crowley J, Bunn PA, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001
3. Bonomi P, Kim K, Fairclough D, et al: Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623-631, 2000
4. Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65:25-32, 1980
5. Brundage MD, Davies D, Mackillop WJ: Prognostic factors in non-small cell lung cancer: A decade of progress. Chest 122:1037-1057, 2002
6. Feld R, Abratt R, Graziano S, et al: Pre-treatment minimal staging and prognostic factors for non-small cell lung cancer. Lung Cancer 17:53-10, 1997 (suppl 1)
7. Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22:330-353, 2004
8. Finkelstein DM, Ettinger DS, Ruckdeschel JC: Long-term survivors in metastatic non-small-cell lung cancer: An Eastern Cooperative Oncology Group Study. J Clin Oncol 4:702-709, 1986
9. Albain KS, Crowley JJ, LeBlanc M, et al: Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9:1618-1626, 1991
10. Paesmans M, Sculier JP, Libert P, et al: Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients-The European Lung Cancer Working Party. J Clin Oncol 13:1221-1230, 1995
11. Hickish TF, Smith IE, O'Brien ME, et al: Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors. Br J Cancer 78:28-33, 1998
12. Schoenlaub P, Sarraux A, Grosshans E, et al: [Survival after cutaneous metastasis: A study of 200 cases]. Ann Dermatol Venereol 128:1310-1315, 2001
13. Fukuoka M, Masuda N, Furuse K, et al: A randomized trial in inoperable non-small-cell lung cancer: Vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol 9:606-613, 1991
14. O'Connell JP, Kris MG, Gralla RJ, et al: Frequency and prognostic importance of pre-treatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 4:1604-1614, 1986
15. Shinkai T, Eguchi K, Sasaki Y, et al: A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother Pharmacol 30:1-6, 1992
16. Langer CJ, Manola J, Bernardo P, et al: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:173-181, 2002
17. Lilenbaum R, Herndon J, List M: Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): A CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. Proc Am SocClin Onc 21:1a, 2002 (abstr 2)
18. Radzikowska E, Glaz P, Roszkowski K: Lung cancer in women: Age, smoking, histology, performance status, stage, initial treatment and survival-Population- based study of 20 561 cases. Ann Oncol 13:1087-1093, 2002
19. ASCO: Clinical practice guidelines for the treatment of unresectable non- small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15:2996-3018, 1997
20. Smaletz O, Scher HI, Small EJ, et al: Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20:3972-3982, 2002
21. Kattan MW, Wheeler TM, Scardino PT: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17:1499-1507, 1999
22. Kattan MW, Zelefsky MJ, Kupelian PA, et al: Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18:3352-3359, 2000